Company	Product	Development
Alpha-Beta Technology	Betafectin	In a 30-patient trial of patients undergoing major chest or abdominal surgery, the antiinfectious Betafectin reduced the number of confirmed infections by 70 percent, compared with the placebo group. The compound is a yeast-derived carbohydrate polymer that binds to the ß-glucan receptor on neutrophils, enhancing their number.
Arcturus Pharmaceutical	Dexchlor-phreniramine	Arcturus initiated phase I trials for a topical formulation of the antihistamine dexchlorphreniramine to treat puritis associated with such skin disorders as contact and atopic dermatitis. The lipid solubility of the formulation enables dexchlorphreniramine to penetrate the outer layer of skin.
BioChem Pharma	3CT	3CT, which inhibits an enzyme that HIV uses to replicate, has received authorization from the Canadian government for "compassionate" use in AIDS patients who haven't responded to other therapies.
BioCryst Pharmaceutical	BCX-34	The Food and Drug Administration (FDA) has granted BCX-34 orphan-drug status to treat T-cell lymphoma. BCX-34 is an inhibitor of the enzyme purine nucleoside phosphorylase. Such inhibition allows the control of proliferating T-cells, a causative factor in cancers.
Cephalon	Myotrophin	Cephalon has begun a European phase II/III trial of Myotrophin, a recombinant insulin-like growth factor-1, in patients with amyotrophic lateral sclerosis.
CoCensys	CCD 1042	CoCensys has begun a 24-patient phase I trial in the U.K. of CCD 1042, its lead anticonvulsant compound that is modeled after naturally occurring neurosteroids that have a calming effect on the central nervous system.
Genelabs Technologies	GLQ223	Genelabs reported results of a 148-patient phase II trial of GLQ223 in patients with AIDS and AIDS-related complex. Patients randomized to AZT, GLQ223, or a combination of both drugs had similar rates of CD4+ cell decline, though data suggests treatment-associated benefits for GLQ223 in clinical, immunologic, and virologic parameters. GLQ223 is a plant-derived formulation of the single-chain ribosome-inactivating protein trichosanthin.
Immunomedics	Immu RAID-LL2	In a phase I/II trial, ImmuRAID-LL2—an imaging agent made up of an antibody fragment labeled with technetium-99m that attaches to lymphoma cells—resulted in clinical-management change, better definition of extent of disease, or added physician confidence in 65 percent of patients.
Immunomedics	Immu RAID-MN3	In a phase II trial, ImmuRAID-MN3—an infectious-disease imaging agent consisting of an antibody fragment labeled with technetium-99m that attaches to granulocytes—was 93 percent accurate in identifying infections in 39 patients.
Magainin Pharmaceutical	MSI-78	In a phase II trial of MSI-78 in which bacteria and fungi were introduced on the skin of 45 volunteers, MSI-78 eradicated fungi, as well as Gram-positive and Gram-negative bacteria. The compound, a synthetic magainin, is currently in a phase IIb/III trial to treat impetigo, a skin infection usually occurring in children.
Medarex	MDX-210	In eight patients in a phase I/II trial, Medarex's Bispecific antibody, MDX-210, primed monocytes to seek out tumor cells. MDX-210 consists of fragments of two monolconal antibodies linked together. One fragment binds to the HER-2 receptor on certain cancer cells. The other binds to the Fc receptor on monocytes.
MedImmune	MelGAM	The New York Blood Center (NYBC) filed a product license application with the FDA for MelGAM—a liquid, intravenous immune globulin treated with a solvent-detergent process to inactivate viruses—for primary humoral immunodeficiencies and for idiopathic thrombocytopenic purpura. MelGAM was developed by Melville Biologics, a division of the NYBC. MedImmune will acquire Melville, including rights to MelGAM.
Miles	Anti-TNF	In a 1000-patient phase III trial, a monoclonal antibody against tumor necrosis factor showed no benefit in reducing mortality among all sepsis patients, though it did show a nonstatistically significant 17 percent reduction in 28-day mortality among patients with sepsis who were also in shock. Miles will conduct a second phase III trial of the product, which is licensed from Chiron, in 600 to 900 patients with septic shock.
Northfield Laboratories	Blood substitute	The firm has received FDA clearance to treat trauma patients with its human-hemoglobin-based blood substitute.
Repligen	rPF4	Repligen has begun three trials with recombinant platelet factor-4, which inhibits the development of new blood vessels, in Kaposi's sarcoma patients. The studies include a 30-patient phase II intralesional, a 20-patient phase I/II subcutaneous, and a 20-patient phase I/II intravenous.
AGBIOTECH		
Ecogen	Condor & Cutlass	Ecogen has received a new product registration from the People's Republic of China to market its *Bacillus thuringiensis*-based bioinsecticides Condor and Cutlass. Roussel-Uclaf, Ecogen's marketing partner in China, expects to begin selling Condor this year.
SyntroVet	MaxiVac-FLU	SyntroVet, a wholly owned subsidiary of Syntro, has received approval from the Department of Agriculture for its vaccine against the swine influenza virus.

—Mike Ginsberg